Skip to main content
SpringerLink
Log in

Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83: 588–593, 2000

    Article  PubMed  CAS  Google Scholar 

  2. Wick W, Steinbach JP, Küker W, Dichgans J, Weller M, One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma Neurology 62: 2113–2115, 2004

    PubMed  CAS  Google Scholar 

  3. Wick W, Weller M, How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience J Clin Oncol 23: 4235–4236, 2005

    Article  PubMed  Google Scholar 

  4. Stupp R, Mason WP, Van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes AA, Cairncross JG, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Eisenhauer E, Mirimanoff RO, On behalf of the European Organization for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma N Engl J Med 352: 997–1003, 2005

    Article  PubMed  Google Scholar 

  5. MacDonald DR, Cascino TL, Schold SC, Cairncross JG, Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8: 1277–1280, 1990

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Johannes-Gutenberg University of Mainz, Mainz, Germany

    Dorothee Koch MD

  2. Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-seyler-str. 3, 72076, Tübingen, Germany

    Wolfgang Wick MD

Authors
  1. Dorothee Koch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Wick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Wick MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koch, D., Wick, W. Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. J Neurooncol 77, 219–220 (2006). https://doi.org/10.1007/s11060-005-9019-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-005-9019-7

Keywords

Search

Navigation